Biohaven Pharmaceutical Holding Stock Analysis

Biohaven Stock Analysis Notes

About 67.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 7.52. Biohaven Pharmaceutical had not issued any dividends in recent years. Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. Biohaven is traded on New York Stock Exchange in the United States. For more info on Biohaven Pharmaceutical Holding please contact Vlad Coric at 203 404 0410 or go to https://www.biohaven.com.

Biohaven Pharmaceutical Investment Alerts

Biohaven Largest EPS Surprises

View All Earnings Estimates

Biohaven Pharmaceutical Environmental, Social, and Governance (ESG) Scores

Biohaven Stock Institutional Investors

Note, although Biohaven Pharmaceutical's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biohaven Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.62 B.

Biohaven Profitablity

Management Efficiency

Biohaven Pharmaceutical has return on total asset (ROA) of (1.0625) % which means that it has lost $1.0625 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.2208) %, meaning that it created substantial loss on money invested by shareholders. Biohaven Pharmaceutical's management efficiency ratios could be used to measure how well Biohaven Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of February 2026, Return On Tangible Assets is likely to drop to -1.34. In addition to that, Return On Capital Employed is likely to drop to -1.81. At this time, Biohaven Pharmaceutical's Non Currrent Assets Other are very stable compared to the past year. As of the 12th of February 2026, Other Current Assets is likely to grow to about 60.2 M, while Total Assets are likely to drop about 388.4 M.

Technical Drivers

As of the 12th of February 2026, Biohaven Pharmaceutical shows the Risk Adjusted Performance of 0.1125, mean deviation of 4.08, and Downside Deviation of 3.9. Biohaven Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Biohaven Pharmaceutical Price Movement Analysis

Biohaven Pharmaceutical Insider Trading Activities

Biohaven Pharmaceutical Outstanding Bonds

Biohaven Pharmaceutical Predictive Daily Indicators

Biohaven Pharmaceutical Corporate Filings

Biohaven Pharmaceutical Forecast Models

Biohaven Pharmaceutical's time-series forecasting models are one of many Biohaven Pharmaceutical's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biohaven Pharmaceutical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Biohaven Pharmaceutical Bond Ratings

Biohaven Pharmaceutical Holding financial ratings play a critical role in determining how much Biohaven Pharmaceutical have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Biohaven Pharmaceutical's borrowing costs.

Biohaven Pharmaceutical Debt to Cash Allocation

Biohaven Pharmaceutical Holding currently holds 36.58 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity.

Biohaven Pharmaceutical Total Assets Over Time

Biohaven Pharmaceutical Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Biohaven Pharmaceutical uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Biohaven Pharmaceutical Debt Ratio

12.0

It appears that most of the Biohaven Pharmaceutical's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Biohaven Pharmaceutical's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Biohaven Pharmaceutical, which in turn will lower the firm's financial flexibility.

Biohaven Pharmaceutical Corporate Bonds Issued

Biohaven Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biohaven Pharmaceutical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biohaven shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Biohaven Pharmaceutical. By using and applying Biohaven Stock analysis, traders can create a robust methodology for identifying Biohaven entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biohaven analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biohaven analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Biohaven Pharmaceutical Holding stock analysis indicators help investors evaluate how Biohaven Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biohaven Pharmaceutical shares will generate the highest return on investment. By understating and applying Biohaven Pharmaceutical stock analysis, traders can identify Biohaven Pharmaceutical position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Understanding Biohaven Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biohaven's accounting equity. The concept of intrinsic value - what Biohaven Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biohaven Pharmaceutical's price substantially above or below its fundamental value.

It's important to distinguish between Biohaven Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biohaven Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biohaven Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.